glp 1 and gip medication Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes glp 1 gip side effects

However, due to safety concerns and lack of clinical approval, its use for any medical purpose is not recommended at this time

Given their non-invasive nature and similar clinical performance, these routes may represent suitable alternatives to intramuscular therapy, particularly in settings requiring long-term management

Weight maintenance: Research shows weight typically regains after discontinuation, suggesting ongoing treatment is needed to maintain benefits

Amylin agonists and dual amylin/ calcitonin receptor agonists are currently under development for the treatment of both obesity and type-2 diabetes (T2D)

H tr iu tr ng c thy ngn lm gim nng thy ngn trong mu